

RealRate











RealRate



AgeX Therapeutics Inc. Rank 62 of 363

The relative strengths and weaknesses of AgeX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AgeX Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 148% points. The greatest weakness of AgeX Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 216%, being 180% points above the market average of 37%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 7,853                |
| Cost of Goods Sold                          | 364                  |
| Intangible Assets                           | 2,709                |
| Liabilities, Current                        | 0                    |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 19                   |
| Other Compr. Net Income                     | 15,532               |
| Other Expenses                              | 800                  |
| Other Liabilities                           | 2,440                |
| Other Net Income                            | 3,514                |
| Other Revenues                              | 1,396                |
| Property and Equipment                      | 90                   |
| Research and Development                    | 5,830                |
| Selling, General and Administrative Expense | 5,647                |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 10,671               |
| Liabilities              | 2,440                |
| Expenses                 | 12,641               |
| Revenues                 | 1,396                |
| Stockholders Equity      | 8,231                |
| Net Income               | -7,731               |
| Comprehensive Net Income | 35                   |
| Economic Capital Ratio   | 216%                 |

